Long-Term US Study Confirms Neurodevelopmental Risks of Valproate in Pregnancy While Validating Safety of Alternative Epilepsy Medications

New BMJ research validates the safety of levetiracetam in pregnancy while reinforcing the link between prenatal valproate exposure and ADHD or autism.

By: AXL Media

Published: Mar 13, 2026, 5:13 AM EDT

Source: Information for this report was sourced from BMJ Group

Confirming Established Risks in Maternal Epilepsy Care

The management of epilepsy during pregnancy presents a significant clinical challenge, as uncontrolled seizures pose life-threatening risks to both the mother and the developing fetus. However, new research published in The BMJ has added substantial weight to the evidence against the use of valproate, a common antiseizure medication. Analyzing data from over 14,000 children, researchers confirmed that prenatal exposure to valproate is strongly associated with an increased risk of neurodevelopmental disorders, including autism and ADHD. These findings reinforce a growing international consensus that valproate should be avoided by women of childbearing age whenever viable alternatives exist.

Comparative Safety of Modern Antiseizure Alternatives

In a significant move toward reassuring expectant mothers, the study found no substantial risk associated with several widely used alternatives, specifically levetiracetam and lamotrigine. These drugs, often prescribed for epilepsy as well as bipolar disorder and migraine prevention, showed no meaningful association with the majority of studied neurodevelopmental outcomes. This validation is critical for clinicians who must balance effective seizure control with fetal safety. By demonstrating that certain modern medications do not carry the same heavy developmental toll as older counterparts, the research provides a clearer roadmap for specialized prenatal care.

Identifying Emerging Signals for Newer Medications

While some drugs were cleared of major risks, the study identified potential "signals" for newer or less-studied medications that warrant further investigation. Specifically, zonisamide showed associations with several neurodevelopmental disorders that researchers say require immediate and continued monitoring. Additionally, topiramate and lamotrigine showed slight potential signals for intellectual disability, though the authors were careful to note that these specific findings were based on small sample sizes. These early indicators serve as a warning to the medical community that the safety profiles of newer antiseizure drugs are not yet fully understood and require long-term observational follow-ups.